Baton Rouge, LANCT07807163Now EnrollingIRB Ready

Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trial in Baton Rouge, LA

Access cutting-edge metastatic head and neck squamous cell carcinoma treatment through this phase 2 clinical trial at a research site in Baton Rouge. Study-provided care at no cost to qualified participants.

Sponsored by Bicara Therapeutics

Quick Self-Assessment

See if you qualify for this Baton Rouge location

Preparing your pre-screening questions…

Expert Care in Baton Rouge

Access metastatic head and neck squamous cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic head and neck squamous cell carcinoma treatment provided free

Apply for This Baton Rouge Location

Check if you qualify for this metastatic head and neck squamous cell carcinoma clinical trial in Baton Rouge, LA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baton Rouge

    Convenient for LA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baton Rouge site if eligible
  4. 4Begin participation

About This Metastatic Head and Neck Squamous Cell Carcinoma Study in Baton Rouge

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). The study aims to demonstrate that the antitumor activity of an alternative dosing regimen of ficerafusp alfa in combination with pembrolizumab is comparable to the weekly ficerafusp alfa regimen in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Sponsor: Bicara Therapeutics

Who Can Participate

Inclusion Criteria

Age ≥18 years on the day the Informed Consent Form is signed.
Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
No prior systemic therapy administered in the R or M setting; and completed systemic therapy \>6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
PD-L1 CPS ≥1.
Measurable disease based on RECIST 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function, as defined in the protocol.

Exclusion Criteria

Disease suitable for local therapy administered with curative intent.
Prior treatment with anti-TGFβ therapy.
Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
Progressive disease \<6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
Life expectancy less than 3 months.
Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
Active autoimmune disease requiring systemic treatment in the past 2 years.
Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
Known history of human immunodeficiency virus (HIV).
Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
Any condition requiring systemic treatment with either corticosteroids (\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
Use of a live or live attenuated vaccine within 4 weeks prior to Screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baton Rouge?

Yes, this clinical trial (NCT07807163) has an active research site in Baton Rouge, LA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Head and Neck Squamous Cell Carcinoma Treatment Options in Baton Rouge, LA

If you're searching for metastatic head and neck squamous cell carcinoma treatment options in Baton Rouge, LA, this clinical trial (NCT07807163) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baton Rouge research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced metastatic head and neck squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic head and neck squamous cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Baton Rouge, LA

See all alzheimers disease clinical trials recruiting in Baton Rouge — not just this study.

Browse Alzheimers Disease Trials in Baton Rouge →

Browse More Trials by Condition

Alzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Baton Rouge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baton Rouge, LA